AVEO Pharmaceuticals ’ Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorab

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months. 06/10/2010
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

This study aimed to evaluate the utility of the AACI for predicting long-term survival in patients with surgically treated non-metastatic clear cell RCC (ccRCC).MethodsData from 698 patients with non-metastatic ccRCC who underwent radical or partial nephrectomy as primary therapy from a multi-institutional Korean collaboration between 1988 and 2015 were retrospectively analyzed. Clinicopathological variables and survival outcomes of those with AACI scores  ≤ 3 (n = 324), 4–5 (n = 292), and ≥ 6 (n = 82) were compared.ResultsPatients with a hig...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Abstract AIM: To provide a comprehensive analysis of the outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for renal cell carcinoma (RCC) in older patients. METHODS: The RESURGE project is a multi-institutional dataset including 24 institutions worldwide collecting data of patients older than 75 years old who underwent RN or PN. RESULTS: Among three already published studies, RN patients were older (p 
Source: Aging Clinical and Experimental Research - Category: Geriatrics Authors: Tags: Aging Clin Exp Res Source Type: research
Conclusions: Pathological complete response with nivolumab in metastatic renal cell carcinoma is rare. This case further highlights the potentially predictive role of immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma and raises questions concerning the role of nephrectomy after immune checkpoint inhibitor therapy. Further studies are needed to better identify predictive factors for treatment response to immunotherapy in metastatic renal cell carcinoma, and to better understand the role of nephrectomy after nivolumab treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: TSR, locoregional recurrence, tumor bed recurrence, and contralateral tumor development are observed patterns of RCC recurrence after RPN. Recurrence was seen in up to 72 months. RPN provides great cancer control and high cure rate when utilized to treat RCC presenting as SRM.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
Abstract OBJECTIVE: Preoperative inflammatory parameters are associated with outcome in renal cell carcinoma; however, their predictive value in tumors with sarcomatoid dedifferentiation (sRCC) is uncertain. We aimed to evaluate the association between preoperative and postoperative inflammatory parameters and the outcome of patients with locoregional and metastatic sRCC who underwent nephrectomy. METHODS AND MATERIALS: After obtaining IRB approval, we identified 230 patients with sRCC treated between 1994 and 2018 with a complete blood count drawn ≤1 month before nephrectomy. Preoperative neutrophil-lymph...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
AbstractBackgroundThere is currently no circulating biomarker for renal cell carcinoma (RCC). The use of adjuvant sunitinib for RCC after nephrectomy is controversial, and a biomarker could help to select the patients at highest risk for recurrence. Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain can be detected in circulating plasma. We therefore investigated whether KIM-1 is associated with worse outcomes in patients with localized RCC after nephrectomy.MethodsIn the ECOG-ACRIN 2805 (ASSURE) trial, 1943 patients with resected high-risk RCC were randomized 1:1:1 to sunitinib, sorafenib, or plac...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractCollecting duct carcinoma (CDC) of the kidney is a rare subtype of renal cell carcinoma (RCC) arising from the distal collecting tubules, characterized by an aggressive phenotype, unfavorable response to several types of systemic agent and a poor prognosis. Recently, treatments with immune checkpoint inhibitors have been widely performed for patients with metastatic RCC; however, no data are available regarding the impact of first-line combination therapy with nivolumab and ipilimumab on metastatic CDC. Here, we report a CDC patient with multiple lymph node metastases who underwent cytoreductive open nephrectomy an...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Abstract INTRODUCTION: Renal cell carcinoma (RCC) with isolated lymph node (LN) involvement (pN1 M0 RCC) is a rare clinical entity associated with a poor prognosis. Prior studies comprised cohorts treated predominantly prior to the introduction of targeted systemic therapy. We therefore examined the natural history of pN1M0 RCC following surgical resection in a contemporary cohort, and evaluated clinicopathologic features associated with survival. PATIENTS AND METHODS: We identified patients aged 18 to 89 years who underwent radical or partial nephrectomy with LN dissection for pN1 M0 RCC from 2006 to 2013 in...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
ConclusionsIn our experience, patients with PSM after PN can be managed conservatively with satisfactory long-term oncological outcomes.ResumenIntroducciónLa nefrectomía parcial (NP) es el tratamiento de elección para el tumor renal pequeño y localizado (cT1). Uno de los puntos de debate respecto a esta técnica es el manejo de los márgenes de resección afectados/positivos (MP). Presentamos los resultados oncológicos a largo plazo en pacientes con MP tras NP manejados conservadoramente.Material y métodosEn nuestro centro entre el año 1990 y 2011 se realiz...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
In conclusion, results showed that adipose microenvironment can regulate the behavior of tumor and non tumor human renal epithelial cells. PMID: 31534630 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology